- Quote, Chart, News
- Snapshot
- Company Report
- Quotes
- Charts
- Key Developments
Recent News- Research
- SEC Filings
- Advisor FYI
- CAPS
- StockScouter
- Earnings Estimates
- Analyst Ratings
- Financial Results
- Insider Trading
- Ownership
- Message Board
- Guided Research
- Research Wizard
- Find Stocks
- Stock Screener
- Stock Power Searches
- Top-Rated Stocks
- Related Links
- Quote Watchlist
- Expert Picks
- E-mail & Alerts
- IPO Center
- Message Boards
- Capital Gains Analysis
News resources
| American International Group Inc (AIG) | 2 stories... |
| LM Ericsson Telephone ADR Reptg 1 Ord Shs Class B (ERIC) | 2 stories... |
| New York Times Co (NYT) | 1 story... |
| DemandTec Inc (DMAN) | 1 story... |
| Comcast Corp (CMCSA) | 1 story... |
| advertisement |
Amgen Inc: All Recent News
- Final Glance: Biotechnology companies 11/24/2009
- NEW YORK (AP) - Shares of some top biotechnology companies were mixed at the close of trading:... Associated Press
- Early Glance: Biotechnology companies 11/24/2009
- NEW YORK (AP) - Shares of some top biotechnology companies are mixed at 10 a.m.:... Associated Press
- Amgen Recognized for Best Pipeline and Best New Drug at Scrip... 11/23/2009
- THOUSAND OAKS, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for Nplate®... PR Newswire
- 5 Top Stocks at Half Price 11/23/2009
- Investors still think highly of these companies, despite their fire-sale prices. At Motley Fool
- 7 Stocks That Are Swimming in Cash 11/22/2009
- But some may need a life preserver. At Motley Fool
- 7 Stocks That Are Swimming in Cash 11/22/2009
- But some may need a life preserver. Motley Fool
- ImmunoGen licenses technology to Amgen for $1M 11/19/2009
- WALTHAM, Mass. (AP) - ImmunoGen Inc. said Thursday that Amgen Inc. licensed rights to a second potential cancer-treatment from the company for $1 million upfront. Associated Press
- Moody's gives negative view on pharma credit 11/19/2009
- NEW YORK (AP) - Moody's Investors Service issued a negative opinion on the pharmaceutical industry Thursday, saying drugmaker credit ratings will be under pressure until early 2012 because they won't be able to fully replace revenue from best-sellers that go off-patent. Associated Press
- This Stock Is a Train Wreck 11/19/2009
- Genzyme's string of missteps has investors nervous. At Motley Fool
- Follow the Smart Money 11/19/2009
- Let (legal) insider trading show you the way. At Motley Fool
- Farewell to Wall St.'s decade of hubris 11/18/2009
- The era will be remembered for 2 burst financial bubbles and a rogue's gallery of scoundrels who rewarded themselves well and delivered very little. MSN Money
- The Type of Stock You Should Never, Ever Buy 11/18/2009
- Heelys stock never had a chance. At Motley Fool
- These Stocks Will Burn You 11/18/2009
- Unless, that is, you follow a few simple steps. At Motley Fool
- Biotech Stocks: Ho-Hum in the Long Run 11/18/2009
- ... At Wall Street Journal
- ($) Is It Really About the Dollar? 11/17/2009
- Don't get wrapped up in the weak-dollar hoopla -- It's only a part of the story. At TheStreet.com
- More News
- Market Report
- News by Symbol
- Today's Investing Articles
- Breaking News
- News by Topic
- News by Industry
- MSNBC News
- Data providers
- Copyright © 2009 Thomson Reuters. Click for Restrictions.
- Quotes supplied by Interactive Data Real-Time Services.